[go: up one dir, main page]

WO2001030790A1 - Composes de ruthenium (ii) demi-sandwich comprenant de l'azote contenant des ligands utilises dans le traitement du cancer - Google Patents

Composes de ruthenium (ii) demi-sandwich comprenant de l'azote contenant des ligands utilises dans le traitement du cancer Download PDF

Info

Publication number
WO2001030790A1
WO2001030790A1 PCT/GB2000/004144 GB0004144W WO0130790A1 WO 2001030790 A1 WO2001030790 A1 WO 2001030790A1 GB 0004144 W GB0004144 W GB 0004144W WO 0130790 A1 WO0130790 A1 WO 0130790A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
mmol
alkyl
optionally substituted
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2000/004144
Other languages
English (en)
Inventor
Robert Edward Morris
Peter John Sadler
Haimei Chen
Duncan Jodrell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Edinburgh
Original Assignee
University of Edinburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9925274.4A external-priority patent/GB9925274D0/en
Priority claimed from GB0016054A external-priority patent/GB0016054D0/en
Priority to DE60022372T priority Critical patent/DE60022372T2/de
Application filed by University of Edinburgh filed Critical University of Edinburgh
Priority to EP00971599A priority patent/EP1224192B1/fr
Priority to JP2001533142A priority patent/JP2003512471A/ja
Priority to AT00971599T priority patent/ATE303393T1/de
Publication of WO2001030790A1 publication Critical patent/WO2001030790A1/fr
Priority to US10/134,404 priority patent/US6750251B2/en
Anticipated expiration legal-status Critical
Priority to US10/848,416 priority patent/US6979681B2/en
Priority to US11/165,372 priority patent/US20050239765A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0046—Ruthenium compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F17/00—Metallocenes
    • C07F17/02—Metallocenes of metals of Groups 8, 9 or 10 of the Periodic Table

Definitions

  • This invention relates to ruthenium (II) compounds, to their use in medicine, particularly for the treatment and/or prevention of cancer, and to a process for their preparation.
  • ruthenium (II) complexes have been proposed for use in treating cancer.
  • US 4980473 discloses 1,10-phenanthroli ⁇ e complexes of ruthenium (II) and cobalt (III) which are said to be useful for the treatment of tumour cells in a subject.
  • Dale et al Anti-Cancer Drug Design (1992), 7, 3-14, describes a metronidazole complex of ruthenium (II) ie, [( ⁇ 6 - 5 C 6 H 6 )RuCl 2 (metronidazole)] and its effect on DNA and on E. coli growth rates.
  • II ruthenium
  • Metronidazole sensitises hypoxic tumour cells to radiation and appears to be an essential element of the complexes of Dale et al. There is no indication in Dale et al that the complexes would be at all effective in the absence of the metronidazole ligand.
  • the present invention provides a novel class of ruthenium (II) complexes having anti-tumour activity.
  • R 1 , R 2 , R 3 , R ⁇ R 5 and R 6 independently represent H, alkyl, -CO 2 R0 aryl or alkylaryl, which latter two groups are optionally substituted on the aromatic ring;
  • R' represents alkyl, aryl or alkaryl;
  • Y is a counterion;
  • m is 0 or 1 ; q is 1, 2 or 3;
  • C is C, to C 12 alkylene, optionally substituted in or on the alkylene chain, bound to two A groups; p is 0 or 1 and r is 1 when p is 0 and r is 2 when p is 1 ; and A and B are: each independently N-donor nitrile ligands; or B is halo and A is an N-donor pyridine ligand, optionally substituted at one or more of the carbon atoms of the pyridine ring; or p is 0, A is NR 7 R 8 and B is NR 9 R 10 , wherein R 7 , R 8 , R 9 and R 10 independently represent H or alkyl, and A and B are linked by an alkylene chain, optionally substituted in or on the alkylene chain; or p is 1, A is NR 7 and B is NR 9 R 10 , wherein R 7 , R 9 and R 10 are as previously defined, and A and B are linked by an alkylene chain, optionally substituted.
  • the compounds of the invention may be in the form of solvates and/or prodrugs.
  • Prodrugs are variants of the compounds of the invention which can be converted to compounds of formula (I) in vivo.
  • the compounds of formula (I) may have one or more chiral centres.
  • they may be in the form of one enantiomer, may be enriched in one enantiomer or may be a racemic mixture.
  • alkyl as used herein includes C, to C 6 alkyl groups which may be branched or unbranched and may be open chain or, when they are C 3 to C 6 groups, cyclic.
  • Unbranched open chain alkyl groups include, for example, methyl, ethyl, propyl, butyl, pentyl and hexyl.
  • Branched open chain alkyl groups include, for example, 2-propyl, 2-butyl and 2-(2- methyl)propyl.
  • Cyclic groups include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
  • the alkyl groups in the compounds of the invention may optionally be substituted.
  • Substituents include one or more further alkyl groups and/or one or more further substituents, such as, for example, cyano, nitro, hydroxyl, haloalkyl, -C0 2 alkyl, halo, thiol (SH), thioether (eg, S-alkyl) and sulfonate.
  • alkylene is defined similarly to the definition of the term “alkyl” but includes C 2 to C 12 groups and is a divalent species with radicals separated by two or more (eg, from two to twelve) carbon atoms linked in a chain.
  • the alkylene groups are straight chain groups.
  • Alkylene groups are optionally substituted in the alkylene chain, preferably with one or more phenylene (eg, 1 ,4-phenylene) and/or -CONR la - groups and/or -NR 2a - groups, where R la and R 2a independently represent H, alkyl, aryl or alkaryl. Preferably, R la and R 2a are H or to C 3 alkyl.
  • phenylene eg, 1 ,4-phenylene
  • R la and R 2a independently represent H, alkyl, aryl or alkaryl.
  • R la and R 2a are H or to C 3 alkyl.
  • aryl as used herein includes aromatic carbocyclic rings such as phenyl and naphthyl and heterocyclic rings such as pyridyl, imidazolyl, pyrrolyl and mranyl.
  • Aryl groups may optionally be substituted with one or more substituents including, for example, alkyl, cyano, nitro, hydroxyl, haloalkyl, -C0 2 alkyl, halo, thiol (SH), thioether (eg, S-alkyl) and sulfonate.
  • alkaryl means alkyl substituted with aryl eg, benzyl.
  • halo means a halogen radical selected from fluoro, chloro, bromo and iodo.
  • haloalkyl means alkyl substituted with one or more halo groups eg, trifluoromethyl.
  • R 1 , R 2 , R 3 , R 4 , R 5 and R 6 may represent H.
  • R 1 may be 2-propyl and R 4 may be methyl, with R 2 , R 3 , R 5 and R 6 all representing hydrogen.
  • R 1 may be phenyl, with R 2 , R 3 , R 4 , R 5 and R 6 all representing hydrogen.
  • R 1 may be -CO 2 R0 such as -C0 2 CH 3 for example, with R 2 , R 3 , R 4 , R 5 and R 6 all representing hydrogen.
  • a and B in the compounds of formula (I) both represent R ⁇ -CN.
  • R n is alkyl, preferably to C 3 alkyl, more preferably methyl.
  • one of A and B in the compounds of formula (I) represents a 4-substituted pyridine and the other represents halo.
  • the pyridine may be substituted at the 4- position by, for example, groups including nitro, cyano and C(0)NR 12 R 13 wherein R 12 and R 13 are independently selected from H and alkyl (eg, to C 6 alkyl).
  • the group at the 4- position of the pyridine ring is preferably an electron withdrawing group.
  • a and B may together represent NR 7 R 8 -(CR 12 R 13 ) n - NR 9 R 10 , wherein R 12 and R 13 are independently H or alkyl or R 12 and R 13 groups, on the same carbon atom or on neighbouring carbon atoms, are linked to form a carbocylic ring and n is an integer from 1 to 4.
  • R 12 and R 13 are both hydrogen and n is 2 or 3, more preferably 2.
  • R 7 , R 8 , R 9 and R 10 are preferably H or methyl and, more preferably, all of R 7 , R 8 , R 9 and R 10 are H.
  • R 8 is absent from A, p is 1 and C is C 4 to Cjo straight chain alkylene (eg, hexylene).
  • Compounds according to this aspect of the invention are so-called dinuclear complexes comprising two ruthenium atoms per complex.
  • dinuclear complexes of the invention are those in which A and B together represent:
  • n0 n'0 x0 x" and y' independently represents an integer from 1 to 12, preferably 1 to 6.
  • Y q" in compounds of formula (I) is a counterion and is only present in the compound when the complex containing the metal ion is charged.
  • Y q" is preferably a non-nucleophilic anion such as PF 6 " , for example.
  • R' and R" are preferably alkyl. Most preferably, both R' and R" are methyl.
  • Compounds of formula (I) may be used in medicine.
  • compounds of formula (I) may be used to treat and/or prevent cancer.
  • the present invention also provides the use of a compound of the invention (ie, a compound of formula (I)) in the manufacture of a medicament for the treatment and/or prevention of cancer.
  • a method of treating and/or preventing cancer which comprises administering to a subject a therapeutically effective amount of a compound of the invention.
  • the compounds of the invention may be used directly against a tumour. Alternatively or additionally, the compounds may be used to prevent or inhibit metastasis and/or to kill secondary tumours. It will be understood that the prevention or inhibition of metastasis is encompassed by the term "preventing cancer", as used herein.
  • the invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising one or more compounds of the invention together with one or more pharmaceutically acceptable excipients.
  • Suitable excipients include diluents and/or carriers.
  • the compounds of the invention may be administered by a number of routes including, for example, orally, parenterally (eg, intramuscularly, intravenously or subcutaneously), topically, nasally or via slow releasing microcarriers.
  • suitable excipients for use in the pharmaceutical compositions of the invention include saline, sterile water, creams, ointments, solutions, gels, pastes, emulsions, lotions, oils, solid carriers and aerosols.
  • compositions of the invention may be formulated in unit or sub-unit dosage form including, for example, tablets, capsules and lozenges and containers containing the composition in a form suitable for parenteral administration.
  • the specific dosage level of the compounds and compositions of the invention will depend upon a number of factors, including the biological activity of the specific compound used and the age, body weight and sex of the subject. It will be appreciated that the subject may be a human or a mammalian animal.
  • the compounds and compositions of the invention can be administered alone or in combination with other compounds.
  • the other compounds may have a biological activity which complements the activity of the compounds of the invention eg, by enhancing its effect in killing tumours or by reducing any side-effects associated with the compounds of the invention.
  • the present invention also provides a process for preparing the compounds of the invention which comprises the reaction of a compound of formula [( ⁇ 6 -C 6 (R 1 )(R 2 )(R 3 )(R 4 )(R 5 )(R 6 ))RuX 2 ], which may be in the form of a monomer or a dimer, with A and B, optionally in the presence of Y q" , in a suitable solvent for the reaction, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , X, A, B and Y are as defined above for the compounds of the invention.
  • Suitable compounds of formula [( ⁇ 6 -C 6 (R 1 )(R 2 )(R 3 )(R 4 )(R 5 )(R°))RuX 2 ] for use as starting materials (starting ruthenium complexes) in the process of the invention include [( ⁇ 6 -C 6 H 6 )RuCl 2 ] 2 , [( ⁇ 6 -C 6 H 6 )RuBr 2 ] 2 , [( ⁇ 6 - C 6 H 6 )RuI 2 ] 2 , [( ⁇ 6 -/?-cymene)RuCl 2 ] 2 , [( ⁇ 6 -/?-cymene)RuBr 2 ] 2 and [( ⁇ 6 -/?- cymene)RuI 2 ] 2 which can be prepared by known methods eg Bennett et al, J.Chem. Soc Dalton Trans., 191 A, 233.
  • the solvent for the reaction may be R U -CN itself.
  • Preferred reaction conditions include stirring the starting ruthenium complex, as described above, in R ⁇ -CN as solvent at room temperature until a sufficient amount of product is formed.
  • the reaction mixture comprises a source of Y q ⁇ , such as a compound of formula (NH + )Y q" eg, NH 4 PF 6 .
  • the reaction may be carried out at room temperature or at elevated temperature (eg, 30°C to 90°C) until a sufficient amount of product is formed; optionally after cooling the reaction mixture.
  • the reaction mixture comprises a source of Y q ⁇ , such as a compound of formula (NH 4 + )Y q" eg, NH 4 PF 6 .
  • Compounds of formula (I) in which A or B is an N-donor pyridine ligand may be obtained, according to the process of the invention, by heating a mixture of the starting ruthenium complex and excess pyridine compound (such as a 1.5- to 3- fold molar excess) in a suitable solvent such as benzene until a sufficient amount of product is formed.
  • the reaction may be carried out under reflux conditions.
  • the precipitate which is formed in the process of the invention comprises or consists of the compound of the invention.
  • the compound of the invention may be isolated from the reaction mixture by separating the precipitate from the liquid phase (eg, by filtration) and then removing the solvent from the precipitate (eg, under reduced pressure).
  • the solid thus formed, which comprises or consists of the compound of the invention may, optionally, be purified eg, by recrystallisation from a suitable solvent (including, for certain compounds of the invention, acetonitrile or acetonitrile/ether (where A and B are R n -CN and R n is methyl) and methanol/ether).
  • a suitable solvent including, for certain compounds of the invention, acetonitrile or acetonitrile/ether (where A and B are R n -CN and R n is methyl) and methanol/ether).
  • Benzoic acid (15.5 g, 0.13 mmol) was added to dry ethanol (100 ml) in a 1 1 flask equipped with a mechanical stirrer, Dewar condenser and cooling bath (dry ice/acetone).
  • NH 3 600 ml was condensed into the flask and Na metal (8.3 g, 0.36 mmol) added in small pieces over a period of 30 min.
  • Na metal 8.3 g, 0.36 mmol
  • the starting material [( ⁇ 6 -C 6 H 5 C 6 H 5 )RuCl 2 ] 2 was prepared as previously described. Ethylenediamine and triethylamine were freshly distilled over Na. Tetrahydrofuran (THF) was dried by distillation from Na- benzophenone. Triphenylmethyl chloride (99%) and adipoyl chloride (98%) were purchased from the Arcos Chemical Co.. All other chemicals were AR grade and were used as received.
  • N,N'-Bis(2'tritylaminoethyl)-l ,6-diamidohexane N-Tritylethyldiamine (1.5 g, 4.96 mmol) and triethylamine (1.0 g, 7.29 mmol) were dissolved in chloroform (35 ml) and cooled in an ice bath. To this solution was added adipoyl chloride (0.36 ml, 2.48 mmol) in chloroform (10 ml) slowly with stirring. After addition, the mixture was refluxed for 2 h and cooled to room temperature. This was filtered to give a clear chloroform filtrate (see below).
  • the compounds are tested on 24- well trays.
  • Cells growing in a flask are harvested just before they become confluent, counted using a haemocytometer and diluted down with media to a concentration of lxlO 4 cells per ml.
  • the cells are then seeded in the 24- well trays at a density of lxlO 4 cells per well (i.e. 1ml of the diluted cell suspension is added to each well).
  • the cells are then left to plate down and grow for 72 hours before adding the compounds of the invention.
  • the Ru complexes are weighed out and made up to a concentration of lmg/ml with deionised water then sonicated until they go into solution.
  • the appropriate volume of the Ru solution is added to 5ml of media to make it up to a concentration of lOO ⁇ M for each drug.
  • This lOO ⁇ M solution is then serially diluted to make up the lO ⁇ M, l ⁇ M and 0.1 ⁇ M solutions.
  • the media is removed from the cells and replaced with 1ml of the media dosed with drug. Each concentration is done in duplicate. A set of control wells are left on each plate, containing media without drug.
  • the cells are left exposed to the drugs for 24 hours and then washed with phosphate buffered saline before fresh media is added.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des composés pouvant être utilisés dans le traitement et/ou la prévention du cancer et représentés par la formule (I) dans laquelle R?1, R2, R3, R4, R5 et R6¿ représentent indépendamment H, alkyle, -CO¿2?R', aryle ou akylaryle, ces deux derniers groupes étant éventuellement substitués sur l'anneau aromatique; R' représente alkyle, aryle ou alkaryle; X est halo, H2O, (R')(R'')SO, R'CO2?-¿ ou (R')(R'')C=O, R'' représentant alkyle, aryle ou alkaryle; Y est un contre-ion; m est 0 ou 1; q est 1, 2, 3; C' est alcoylène C¿1?-C12, éventuellement substitué dans ou sur la chaîne alcoylène, lié à deux groupes A; p est 0 ou 1 et r est 1 lorsque p est 0 et r est 2 lorsque p est 1; et A et B sont chacun indépendamment des ligands de nitrile de N donneurs; ou B est halo et A est un ligand de pyridine de N donneurs, éventuellement substitué à un ou plusieurs des atomes de carbone de l'anneau de pyridine; ou p est 0, A est NR?7R8¿ et B est NR?9R10, R7, R8, R9 et R10¿ représentant indépendamment H ou alkyle, et A et B sont liés par une chaîne alcoylène, éventuellement substitués dans ou sur la chaîne alcoylène; ou p est 1, A est NR7 et B est NR?9R10, R7, R9 et R10¿ étant définis précédemment, et A et B sont liés par une chaîne alcoylène, éventuellement substitués.
PCT/GB2000/004144 1999-10-27 2000-10-26 Composes de ruthenium (ii) demi-sandwich comprenant de l'azote contenant des ligands utilises dans le traitement du cancer Ceased WO2001030790A1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AT00971599T ATE303393T1 (de) 1999-10-27 2000-10-26 Halbsandwich ruthenium(ii)-verbindungen mit einem stickstoff-haltigen liganden zur krebstherapie
JP2001533142A JP2003512471A (ja) 1999-10-27 2000-10-26 窒素および配位子を含む癌治療用の半サンドイッチ状ルテニウム（ｉｉ）化合物
DE60022372T DE60022372T2 (de) 1999-10-27 2000-10-26 Halbsandwich ruthenium(ii)-verbindungen mit einem stickstoff-haltigen liganden zur krebstherapie
EP00971599A EP1224192B1 (fr) 1999-10-27 2000-10-26 Composes de ruthenium (ii) demi-sandwich comprenant de l'azote contenant des ligands utilises dans le traitement du cancer
US10/134,404 US6750251B2 (en) 1999-10-27 2002-04-26 Half-sandwich ruthenium (II) compounds comprising nitrogen containing ligands for treatment of cancer
US10/848,416 US6979681B2 (en) 1999-10-27 2004-05-18 Half-sandwich ruthenium (II) compounds comprising nitrogen containing ligands for treatment of cancer
US11/165,372 US20050239765A1 (en) 1999-10-27 2005-06-23 Half-sandwich ruthenium (II) compounds comprising nitrogen containing ligands for treatment of cancer

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9925274.4 1999-10-27
GBGB9925274.4A GB9925274D0 (en) 1999-10-27 1999-10-27 Ruthenium (II) compounds
GB0016054.9 2000-06-30
GB0016054A GB0016054D0 (en) 2000-06-30 2000-06-30 Ruthenium (II) compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/134,404 Continuation US6750251B2 (en) 1999-10-27 2002-04-26 Half-sandwich ruthenium (II) compounds comprising nitrogen containing ligands for treatment of cancer

Publications (1)

Publication Number Publication Date
WO2001030790A1 true WO2001030790A1 (fr) 2001-05-03

Family

ID=26244569

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/004144 Ceased WO2001030790A1 (fr) 1999-10-27 2000-10-26 Composes de ruthenium (ii) demi-sandwich comprenant de l'azote contenant des ligands utilises dans le traitement du cancer

Country Status (8)

Country Link
US (3) US6750251B2 (fr)
EP (1) EP1224192B1 (fr)
JP (1) JP2003512471A (fr)
AT (1) ATE303393T1 (fr)
DE (1) DE60022372T2 (fr)
DK (1) DK1224192T3 (fr)
ES (1) ES2248136T3 (fr)
WO (1) WO2001030790A1 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750251B2 (en) * 1999-10-27 2004-06-15 The University Court, The University Of Edinburgh (Uk) Half-sandwich ruthenium (II) compounds comprising nitrogen containing ligands for treatment of cancer
WO2006018649A1 (fr) * 2004-08-20 2006-02-23 The University Court Of The University Of Edinburgh Composes arene-ruthenium (ii) et leur utilisation dans la therapie du cancer.
US7241913B2 (en) 2003-04-30 2007-07-10 The University Court Of The University Of Edinburgh Ruthenium compounds
WO2007101997A1 (fr) * 2006-03-07 2007-09-13 The University Court Of The University Of Edinburgh Composes comprenant du ruthenium (ii)
WO2007128158A1 (fr) 2006-05-09 2007-11-15 Ecole Polytechnique Federale De Lausanne (Epfl) COMPLEXES DE MÉTAUX DE TRANSITION PERMETTANT d'INHIBER LA RÉSISTANCE DANS LE TRAITEMENT DU CANCER ET DES MÉTASTASES
CN100362005C (zh) * 2002-07-05 2008-01-16 爱丁堡大学董事会 钌的抗癌络合物
WO2011044472A1 (fr) * 2009-10-08 2011-04-14 Angus Chemical Company Polyamines pauvres en voc
WO2013038395A1 (fr) 2011-09-16 2013-03-21 Universidade De Lisboa Complexes de métaux de transition pour applications pharmaceutiques
WO2013136296A2 (fr) 2012-03-14 2013-09-19 Universidade De Lisboa Composés de ruthénium et de fer organométalliques solubles dans l'eau présentant des ligands hétéroaromatiques
US9751081B2 (en) 2014-12-01 2017-09-05 Clemson University Self-regenerating antioxidant catalysts and methods of using the same

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0610062D0 (en) * 2006-05-19 2006-06-28 Univ Edinburgh Ruthenium (ll) compounds
US8383673B2 (en) * 2010-03-19 2013-02-26 City University Of Hong Kong Nitridoosmium(VI) complexes for treatment of cancer
US9290528B1 (en) 2013-03-15 2016-03-22 University Of Kentucky Research Foundation Light-activated compounds
US10053480B1 (en) 2017-10-11 2018-08-21 King Saud University Anti-quorum and DNA cleaving agent

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980473A (en) * 1985-01-18 1990-12-25 The Trustees Of Columbia University In The City Of New York Chemical probes for left-handed DNA and chiral metal complexes as Z-specific anti-tumor agents
JPH11209314A (ja) * 1997-09-30 1999-08-03 Takasago Internatl Corp シクロオクタジエン類の製造方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980472A (en) 1983-06-23 1990-12-25 American Cyanamid Company Method of making (3-amino-1H-pyrazol-4-yl) (aryl)methanones
EP0191096B1 (fr) 1984-07-24 1989-09-13 ASTA Pharma AG Compositions de ruthenium a effet inhibiteur de tumeurs
EP0188585A1 (fr) 1984-07-24 1986-07-30 Byk Gulden Lomberg Chemische Fabrik GmbH Compositions de ruthenium a effet inhibiteur de tumeurs
US4699978A (en) 1985-01-18 1987-10-13 The Trustees Of Columbia University In The City Of New York Site-specific chiral ruthenium (II) and cobalt (III) antitumor agents
US5225556A (en) 1985-01-18 1993-07-06 The Trustees Of Columbia University In The City Of New York Chemical probes for left-handed DNA and for A-DNA; chiral metal complexes as Z-specific antitumor agents and as double strand cleavers
US5386044A (en) 1993-11-30 1995-01-31 E. I. Du Pont De Nemours And Company Polyhaloaromatic ruthenium complexes and reactions thereof
US5708022A (en) 1994-10-28 1998-01-13 Procept, Inc. Method for inhibiting immune response
AU4017695A (en) 1994-10-28 1996-05-23 Procept, Inc. Ruthenium complexes and their use as immunosuppressive agents
ATE303393T1 (de) * 1999-10-27 2005-09-15 Univ Court The University Of E Halbsandwich ruthenium(ii)-verbindungen mit einem stickstoff-haltigen liganden zur krebstherapie
GB0016052D0 (en) * 2000-06-30 2000-08-23 Univ Edinburgh Ruthenium (II) compounds
GB0028025D0 (en) 2000-11-17 2001-01-03 Univ York Compounds
GB0215526D0 (en) * 2002-07-05 2002-08-14 Univ Edinburgh Anticancer compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980473A (en) * 1985-01-18 1990-12-25 The Trustees Of Columbia University In The City Of New York Chemical probes for left-handed DNA and chiral metal complexes as Z-specific anti-tumor agents
JPH11209314A (ja) * 1997-09-30 1999-08-03 Takasago Internatl Corp シクロオクタジエン類の製造方法

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
ARONSON, REES; ELSEGOOD, MARK R. J.; STEED, JONATHAN W.; TOCHER, DEREK A.: "The reactions of [Ru(.eta.6-arene)Cl2]2 compounds with a series of aminopyridine ligands", POLYHEDRON (1991), 10(15), 1727-32, vol. 10, no. 15, 1991, pages 1727 - 1732, XP000980304 *
BENNETT, MARTIN A.; SMITH, ANTHONY K.: "Arene ruthenium(II) complexes formed by dehydrogenation by cyclohexadienes with ruthenium(III) trichloride", J. CHEM. SOC., DALTON TRANS. (1974), (2), 233-41, no. 2, 1974, pages 233 - 241, XP000978668 *
CETINKAYA, BEKIR; OZDEMIR, ISMAIL; BINBASIOGLU, BEYHAN; DURMAZ, RIZA; GUNAL, SELAMI: "Antibacterial and antifungal activities of complexes of ruthenium (II)", ARZNEIM.-FORSCH., vol. 49, no. 6, 1999, pages 538 - 540, XP000978665 *
CRABTREE, ROBERT H.; PEARMAN, ALAN J.: "Arene-ruthenium complexes containing nitrogen donor ligands", J. ORGANOMET. CHEM., vol. 141, no. 3, 1977, pages 325 - 330, XP000978845 *
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; PANDEY, D. S. ET AL: "Synthesis and characterization of [Ru(.eta.6-C6Me6)Cl2(CNPy)] and [Cl2(.eta.6-C6Me6)Ru(.mu.-CNPy)Ru(.eta.6-C6Me6)Cl2] and reactivity of [Ru(.eta.6-C6Me6)Cl2(CNPy)] with various bases", XP002158758, retrieved from STN Database accession no. 125:11077 *
ELSEGOOD, MARK R. J.; TOCHER, DEREK A.: "The synthesis of new paracyclophane complexes of ruthenium(II)", J. ORGANOMET. CHEM. (1988), 356(1), C29-C31, vol. 356, no. 1, 1988, pages C2 - C31, XP000978667 *
GARCIA, GABRIEL; SOLANO, ISABEL; SANCHEZ, GREGORIO; SANTANA, MARIA: "Reactivity of [{(.eta.6-arene)RuCl(.mu.-Cl)}2] towards some potentially bidentate ligands. Molecular structure of [(.eta.6-p-cymene)RuCl(taz)]PF6 (p-cymene = p-MeC6H4CH-Me2; taz = 4-amino-2,6-dimethyl-5-oxo-3-thioxo-2,3,4,5-tetrahydro-1,2,4-triazine)", J. ORGANOMET. CHEM., vol. 467, no. 1, 1994, pages 119 - 126, XP000978847 *
GUPTA, DHARMENDRA KUMAR; SAHAY, ABHAYA NAND; PANDEY, DAYA SHANKAR: "Synthesis, characterization, reactivity and structure of some mono and binuclear (.eta.6-p-cymene)ruthenium(II) complexes", J. ORGANOMET. CHEM., vol. 568, no. 1-2, 1998, pages 13 - 20, XP002158757 *
HUNG, YANN; KUNG, WEI-JEN; TAUBE, HENRY: "Aquo chemistry of monoarene complexes of osmium(II) and ruthenium(II)", INORG. CHEM., vol. 20, no. 2, 1981, pages 457 - 463, XP000978614 *
INDIAN J. CHEM., SECT. A: INORG., BIO-INORG., PHYS., THEOR. ANAL. CHEM. (1996), 35A(5), 434-7 *
JENSEN, SVEND B.; RODGER, SUSAN J.; SPICER, MARK D.: "Facile preparation of .eta.6-p-cymene ruthenium diphosphine complexes. Crystal structure of [(.eta.6-p-cymene)Ru(dppf)Cl]PF6", J. ORGANOMET. CHEM., vol. 556, no. 1-2, 1998, pages 151 - 158, XP000980257 *
MUELLER, JOERN; QIAO, KE; SIEWING, MICHAEL; WESTPHAL, BERND: "(.eta.6-Arene)(.eta.4-buta-1,3-diene)ruthenium(0) complexes synthesis, properties as well as crystal structure of (benzene)(butadiene)ruthenium", J. ORGANOMET. CHEM., vol. 458, no. 1-2, 1993, pages 219 - 224, XP000978666 *
PATENT ABSTRACTS OF JAPAN vol. 1999, no. 13 30 November 1999 (1999-11-30) *
PATHAK, SATYAJIT; GUPTA, D. K.; SAHAY, A. N.; PANDEY, D. S.: "Synthesis and characterization of [{Ru(.eta.6-C6Me6)Cl2}2(.mu.-DCBT)] and its reaction with EPh3 (E = P, As, Sb), 2,2'-bipyridine and 1,10'-phenanthroline", INDIAN J. CHEM., SECT. A: INORG., BIO-INORG., PHYS., THEOR. ANAL. CHEM., vol. 37A, no. 2, 1998, pages 165 - 168, XP000980568 *
PERTICI, PAOLO; SALVADORI, PIERO; BIASCI, ANDREA; VITULLI, GIOVANNI; BENNETT, MARTIN A.; KANE-MAGUIRE, LEON A. P.: "Synthesis of the arene complex bis[dichloro(methylo-toluate)ruthenium] and separation of its diastereomeric (-)(S)-1-phenylethylamine adducts", J. CHEM. SOC., DALTON TRANS., no. 2, 1988, pages 315 - 320, XP000978842 *
SOLORZANO, CARMEN; DAVIS, MICHAEL A.: "Preparation of arene ruthenium(II) complexes with activated ligands", INORG. CHIM. ACTA, vol. 97, no. 2, 1985, pages 135 - 141, XP000980284 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750251B2 (en) * 1999-10-27 2004-06-15 The University Court, The University Of Edinburgh (Uk) Half-sandwich ruthenium (II) compounds comprising nitrogen containing ligands for treatment of cancer
US6979681B2 (en) * 1999-10-27 2005-12-27 University Court, The University Of Edinburgh Half-sandwich ruthenium (II) compounds comprising nitrogen containing ligands for treatment of cancer
CN100362005C (zh) * 2002-07-05 2008-01-16 爱丁堡大学董事会 钌的抗癌络合物
US7241913B2 (en) 2003-04-30 2007-07-10 The University Court Of The University Of Edinburgh Ruthenium compounds
WO2006018649A1 (fr) * 2004-08-20 2006-02-23 The University Court Of The University Of Edinburgh Composes arene-ruthenium (ii) et leur utilisation dans la therapie du cancer.
WO2007101997A1 (fr) * 2006-03-07 2007-09-13 The University Court Of The University Of Edinburgh Composes comprenant du ruthenium (ii)
WO2007128158A1 (fr) 2006-05-09 2007-11-15 Ecole Polytechnique Federale De Lausanne (Epfl) COMPLEXES DE MÉTAUX DE TRANSITION PERMETTANT d'INHIBER LA RÉSISTANCE DANS LE TRAITEMENT DU CANCER ET DES MÉTASTASES
US9018199B2 (en) 2006-05-09 2015-04-28 Ecole Polytechnique Federale De Lausanne (Epfl) Transition metal complexes for inhibiting resistance in the treatment of cancer and metastasis
WO2011044472A1 (fr) * 2009-10-08 2011-04-14 Angus Chemical Company Polyamines pauvres en voc
CN102666473A (zh) * 2009-10-08 2012-09-12 安格斯化学公司 低voc多胺
WO2013038395A1 (fr) 2011-09-16 2013-03-21 Universidade De Lisboa Complexes de métaux de transition pour applications pharmaceutiques
WO2013136296A2 (fr) 2012-03-14 2013-09-19 Universidade De Lisboa Composés de ruthénium et de fer organométalliques solubles dans l'eau présentant des ligands hétéroaromatiques
US9751081B2 (en) 2014-12-01 2017-09-05 Clemson University Self-regenerating antioxidant catalysts and methods of using the same

Also Published As

Publication number Publication date
ES2248136T3 (es) 2006-03-16
US6979681B2 (en) 2005-12-27
DE60022372D1 (de) 2005-10-06
ATE303393T1 (de) 2005-09-15
JP2003512471A (ja) 2003-04-02
US20050239765A1 (en) 2005-10-27
US20030023088A1 (en) 2003-01-30
EP1224192A1 (fr) 2002-07-24
DK1224192T3 (da) 2006-01-02
US20040220166A1 (en) 2004-11-04
DE60022372T2 (de) 2006-06-08
US6750251B2 (en) 2004-06-15
EP1224192B1 (fr) 2005-08-31

Similar Documents

Publication Publication Date Title
US6750251B2 (en) Half-sandwich ruthenium (II) compounds comprising nitrogen containing ligands for treatment of cancer
US7232919B2 (en) Platinum compounds
Qiu et al. Synthesis, crystal structure and antitumor effect of a novel copper (II) complex bearing zoledronic acid derivative
EP1558620B1 (fr) Complexes de ruthenium anticancereux
EP1294732B1 (fr) Composes de ruthenium (ii) a utiliser dans le traitement du cancer
EP0164970B1 (fr) Compositions pharmaceutiques antitumeurs contenant des complexes phosphinohydrocarbures-or, -argent ou -cuivre
FI82941C (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara titanocenkomplex.
AU619881B2 (en) Platinum (IV)-diamine complex, method for the preparation of this compound, preparation with an anti-tumour action, which contains at least one platinum compound, and shaped preparation with an anti-tumour action
US7241913B2 (en) Ruthenium compounds
AU4551800A (en) Ruthenium dimeric complexes suitable as antimetastatic and antineoplastic agents
HK1084954B (en) Ruthenium(ii) complexes for the treatment of tumors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10134404

Country of ref document: US

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 533142

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000971599

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000971599

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2000971599

Country of ref document: EP